Review Article | Open Access
Naveen Dhawan, Blaze Emerson, Romana Popara, Catherine Lin, Adam Rawji, Rita Zeiden, Leeda Rashid, Pwint Phyu, Jaya Bahl, Vineet Gupta, "Are Attributes of Pregnancy and the Delivery Room Experience Related to Development of Autism? A Review of the Perinatal and Labor Risk Factors and Autism", International Scholarly Research Notices, vol. 2014, Article ID 290837, 13 pages, 2014. https://doi.org/10.1155/2014/290837
Are Attributes of Pregnancy and the Delivery Room Experience Related to Development of Autism? A Review of the Perinatal and Labor Risk Factors and Autism
Autism is a neurodevelopmental disorder marked by severe deficits in social communication and interactions. It is a complex condition that lacks an established preventive method, warranting a need for research to identify possible environmental triggers. The identification of external factors particularly perinatal risk factors forms the initial critical step in preventing and alleviating risks. We conducted a literature review to assess evidence suggested in the worldwide literature. Perinatal risk factors that have a suggested association include β2 adrenergic receptor agonists, labor induction and augmentation, maternal infection and disease (i.e., antiphospholipid syndrome), antiepileptic drugs, cocaine use, and oral supplements. Smoking has not been found to have a direct association. Pollutants, selective serotonin reuptake inhibitors, artificial insemination, and fertility medications may have a link, but results are often conflicted. Factors related to the delivery room experience may be associated with meconium aspiration syndrome, birth weight, and labor time. Several risk factors during the pregnancy and labor periods have been associated with autism; yet further studies with large populations are needed to establish definitive associations. The fact that several risk factors during the prenatal and labor periods are implicated in autism should prompt the medical community to focus on the pregnancy and labor periods as preventive measures to curb the incidence of autism.
Autism is a complex condition that lacks an established method of prevention; thus there is a need for research to identify its possible causative factors. Identification of environmental factors is the first step in preventing and mitigating risks by primary prevention . Statistical estimates show that one out of every 88 individuals in the United States is diagnosed with autism. The condition may be defined as a chronic neurodevelopmental disorder that first becomes prevalent in an individual during his/her early childhood. Consequently, autism results in a patient experiencing a life that is marked by the ongoing challenge of its negative effects on communication and interaction with others. The disorder is debilitating for the patient and immensely challenging for his/her family. An initial diagnosis of autism occurs as an individual is noticeably unable to achieve certain early childhood milestones in terms of communication and socialization. Furthermore, while the incidence and the prevalence of autism also tend to raise on an ever-increasing basis, public health concerns over the disorder have also been coupled with concerns over its etiology, which is still in the investigative stage of clinical research .
Initial research efforts, which were embarked upon during the 1950s, assert that complications in a given pregnancy, the birthing process, and the incidence of autism are linked. Over the past several decades, continuing research has been conducted, and much literature has been published that has supported the existence of the links between autism and factors that relate to pre-, peri-, and neonatal care. Such commonly identified, prenatal risk factors may include advanced-aged parents, a short gestation period, low birth weight, hyperbilirubinemia, and breech presentation . Another key factor may be the use of any prenatal, prescription medication [4–6].
Autism, to reiterate, impairs an individual’s ability to use language to effectively communicate and navigate social situations. The assertion that autism patients engage in repetitive, behavioral patterns has arguably become stereotyped. The symptoms of autism become notable in patient in the first three years of life and may necessitate lifelong care that must be provided by family members, guardians, or healthcare professionals. Autism and autism spectrum disorders (ASDs), including Asperger’s syndrome and pervasive developmental disorder, have become increasingly diagnosed over the past decade. Accordingly, population studies, which have been conducted by the United States Centers for Disease Control and Prevention, have reported a prevalence of ASDs of 1 of 68 children at risk.
It should be noted, however, that, from a stand-alone perspective, each of the factors (as listed above) that link autism with pre-, peri-, and neonatal care does not correlate consistently as the incidence of autism is reviewed in terms of its cross-reference amongst various research studies. It should also be noted that, despite ongoing research efforts, relatively little has yet been divulged regarding delivery-room attributes that may be directly or indirectly associated with the incidence of autism. Furthermore, the nature of the precise catalyst of autism has not been revealed as of yet.
Early diagnosis of autism and any subsequent related intervention(s) may serve to alleviate the challenges that are faced by those individuals, who must manage the effects of autism on an ongoing basis, including patients, their guardians and/or families, and related healthcare professionals. The following narrative review aims to better understand the existing evidence for perinatal and labor-related associations with autism.
The etiology of autism is unknown, although perinatal and neonatal exposures have been the focus of recent epidemiologic research . Exposure to certain medications such as perinatal medications, antiepileptic drugs, supplements, and SSRIs has been studied as well as drug exposure to cocaine and smoking. Artificial insemination and fertility medications, meconium aspiration syndrome, and birth weight have also all been subjects of focus and the respective association with pregnancy and neurodevelopmental complications such as autism. Several studies have suggested the association between perinatal factors and the onset of autism. A recent case control study done in New South Wales, Australia, focused on determining risk factors for autism. Four factors were shown to be significantly associated with autism: being male, premature birth, maternal age greater than or equal to 35 years, and mothers born outside of Australia, with highest risk found in mothers from North-East or South-East Asia . A separate study from Western Australia concluded that autistic children generally had parents who were older and had greater frequencies of threatened abortions, epidural anesthesia, labor induction, and labor duration of less than 1 hour. These children were more often born first, had a low Apgar score, and tended to have more complications . Similar studies using a Swedish medical birth registry observed different factors that affected autism spectrum disorders. The researchers found that prematurity, low Apgar scores, growth restriction, or macrosomia, and if the mother was from sub-Saharan Africa or East Asia had a positive correlation with autism spectrum disorders . Information obtained from the Finnish prenatal study of autism and autism spectrum disorders correlated advanced paternal age with an increased risk of ASD . A group in Norway assessed the association between interpregnancy lengths and ASD and found that interpregnancy intervals for less than 9 months and interpregnancy between 9 and 11 months carried an increased risk for ASD .
Further evidence is suggested by other studies. Subjects used in an Australian study were diagnosed with autism spectrum disorder and compared to control subjects. The mothers of autistic children were studied, and it was demonstrated that the cases with autism had more pregnancy complications. The mothers had greater frequencies of threatened abortions, epidural caudal anesthesia use, labor induction, and labor duration of less than one hour. They were more likely to have experienced fetal distress, been delivered by an elective or emergency cesarean section, and had an Apgar score of less than 6 at one minute. It was concluded that although autism is unlikely to be caused by a single obstetric factor, there was an increased prevalence of obstetric complications among autism cases that is most likely due to underlying genetic factors and an interaction of these factors with the environment . Another Australian study evaluated maternal conditions and perinatal characteristics associated with ASD and intellectual disability. Although a weak correlation was found between poor intrauterine environments and ASD with intellectual disabilities, there was no relationship found between ASD without intellectual disabilities and perinatal factors .
ASD may involve additional pathologies at the neuroanatomical level. A recent study illustrates that the neuropathology of some individuals who are diagnosed as having ASD may actually also have focal cortical dysplasias, which could explain the high incidence of sensory irregularities and seizures in ASD diagnosed patients . Thus, focal cortical dysplasias may be a risk factor for ASD patients.
No specific article examined specific aspects such as room temperature, lack of equipment, time spent with the mother, or proximity to other neonates. However, some sources did cite other factors that could potentially be associated with the delivery room itself. These include the type of birth, such as whether it was breech, a prolonged birth, or an induced birth, along with various forms of fetal measures such as birth cry, fetal distress, low heart rate, or high fetal blood pressure [2, 3, 13–15, 60]. Further, a possible association exists with ventilation of neonates . Feeding practices have also been looked at, as well as maternal states such as high temperature or an unhappy maternal emotional state [17–19, 58]. Lastly, the environmental impact of perinatal air pollutants has also been observed [20, 21]. Because these studies have pointed to all of these various factors which in and of themselves can all occur within a delivery room atmosphere, they warrant a further look into even more specific delivery room attributes to see if there is a more direct association between them and autism.
2.1. β2 Adrenergic Receptor Agonists
Beyond the cases conducted to study the relationship between pregnancy complications and augmented childbirth to autism, several studies have been done to investigate the association between prenatal exposures to β2 adrenergic receptor agonists to autism spectrum disorders. These agents include terbutaline, which is commonly used as a tocolytic and a bronchodilator in obstetrics. Terbutaline can cross the placenta and potentially affect the developing neonatal brain . In a study of neonatal rats, Zerrate et al. found neuroinflammatory and behavioral changes, similar to that in autism, after administering terbutaline to subjects. The results demonstrated that terbutaline increased microglial activation in the subjects’ cerebral cortex, cerebellar, and cerebrocortical white matter .
Nucleotide polymorphism of the β2 adrenergic receptor gene has also been implicated as risk factors for autism, namely, Gly 16 and Glu 27 [24, 25]. The researchers of independent subjects and dizygotic twins found that activation of receptors with either polymorphism has been link with increased signaling, secondary to decreased downregulation of the β2 adrenergic receptor gene. Critics of these genetic predisposition argued that since many genes are involved in the etiology of autism, the role of any single gene polymorphism in causing autism is small. The effect of each gene is further diluted by variable penetrance . In clinical studies, researchers from Kaiser Permanente Northern California Hospitals examined 291 children born from 1995 to 1999, compared to 284 controls. They showed that there was no evidence linking β2 adrenergic receptor agonist exposure in pregnancy with an increase in autism risk, except exposure to terbutaline during the third trimester for more than two days [26, 62]. The authors suggested that future studies with larger sample sizes would be helpful to endorse or challenge their findings.
Based on aggregated evidence from animal and human studies, Witter et al. proposed that permanent changes in autonomic tone could result in neurological changes in the fetus, especially after two or more weeks of high dose β2 adrenergic receptor agonist exposure. These functional and behavioral changes may contribute to the signs and symptoms of autism .
2.2. Maternal Disease
In addition to environmental factors, infection and disease may play a role in the development of autism. Children born to mothers with antiphospholipid syndrome were observed to have a higher frequency of autism spectrum disorders in comparison to mothers without antiphospholipid syndrome, which further supports findings that perinatal complications increase the risk of autism in children . Another study was organized to determine ASD in children born preterm and the role of exposure to perinatal inflammation. It was a review that covered the evidence supporting the idea that prenatal infection on the central nervous system may increase the incidence of autism spectrum disorders . An increase in C-reactive protein indicates inflammation, which is common in infection. This increase in C-reactive protein has been found to have a correlation with a risk for autism spectrum disorders .
2.3. Antiepileptic Drugs
Although it has been shown that autism is unlikely to be caused by a single factor, there have been many studies conducted studying the relationship between the use of certain medications during pregnancy and the associated risk of autism. For example, the increased prevalence of the use of anticonvulsant medications during pregnancy is correlated with an increased risk of autism. Valproate is used for the treatment of epilepsy and other neuropsychological disorders and is considered one of the only available treatment options for women of childbearing potential . Recent studies, however, have shown that exposure to valproate during pregnancy indicates a significantly increased risk of autism spectrum disorder, even after adjusting for maternal epilepsy. In fact, valproate use during pregnancy showed an 11.3% increased risk in developmental malformations, and it relied heavily on the dosage prescribed . Women who were prescribed increased doses of valproic acid showed a twofold increase in risk of developmental malformations and significantly reduced intelligence . Studies exposing pregnant rats and mice to valproate demonstrated increased autistic-like behaviors in the offspring. This behavior included social behavior deficits, increased repetitive behaviors, and deficits in communication. The animal studies performed by Roullet have been used as a model to ameliorate and improve upon studies that focus on the association between the risk of autism and the maternal need for anticonvulsants . The current recommendation of health care professionals is to avoid anticonvulsant drug use such as valproate during pregnancy. It is important, however, to assess the intrinsic iatrogenic risk of birth defects or perinatal complications and the general safety for the expectant mother before discontinuing anticonvulsants .
2.4. Oral Supplements
Prenatal supplements are an important component of a healthy pregnancy. Prenatal folic acid supplements have been shown to reduce the risk of neural tube defects in children and are associated with a lower risk of autistic disorder . In this study following 270 children, of the children whose mothers took folic acid, 0.1% developed autistic disorder . Those children whose mothers were not exposed to folic acid comprised 0.21% of the group. This study also analyzed the use of fish oil supplements, which showed no association with autistic disorder . Although no causality was found, it was determined that prenatal folic acid supplements taken during pregnancy were associated with a decreased risk of autistic disorder. Vitamin D, which has a unique role in brain homeostasis, embryogenesis and neurodevelopment, neural differentiation, and gene regulation, has recently been proposed as a possible environmental risk factor for autism during early childhood. Children with autism had significantly lower serum levels of 25-hydroxy vitamin D than healthy children. On the other hand, the involvement of maternal vitamin D during pregnancy in autism requires proper investigation. Recent studies have shown that a wide range of disorders, including neuropsychiatric disorders and autism, are associated with increased homocysteine levels in biological fluids. Homocysteine is an amino acid, which plays several important roles in human physiology. Various B vitamins such as B6 (pyridoxine), B12 (cobalamin), and B9 (folic acid) are required as cofactors by the enzymes involved in homocysteine metabolism. Therefore, it is crucial to monitor the homocysteine levels in body fluids of autistic children. It can provide information on genetic and physiological diseases, improper lifestyle (including dietary habits), and a variety of pathological conditions.
2.5. Illicit Drug Exposure, Smoking, and Pollutants
Drug exposure may have very serious complications during pregnancy. A study was conducted to evaluate the association between autism and developmental abnormalities in children with perinatal cocaine exposure. It was concluded that most of the cases had language delays and difficulties with expressive skills and communication disorders. Significant neurodevelopmental abnormalities were observed and a high frequency of autism was found in children exposed to cocaine, especially in comparison to those exposed to alcohol or opiates alone .
Smoking has been found to be an environmental hazard. Studies have been done determining the effects of smoking in a pregnant patient and the risk of autism in the mother’s offspring. Epidemiological data were obtained from children with autism, including residential history of the mother, which was compared to the traffic-related air pollution assigned to each location using measures from the Environmental Protection Agency’s Air Quality System data. It was assessed that maternal smoking was related to a modest increase in the risk of Pervasive Developmental Disorders, however, there was no known association between maternal smoking and childhood autism . Interestingly, the amount of air pollution that a mother and child were exposed to including traffic related air pollution and nitrogen dioxide, both during pregnancy and during the first year of life, was associated with autism .
Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs currently and increasingly prescribed for anxiety disorders and depression. These drugs, such as Fluoxetine, Sertraline, and Citalopram, work by inhibiting the reuptake of the neurotransmitter serotonin, resulting in a greater amount of serotonin at the synapse. Much like anticonvulsants and other drug exposures, the use of SSRIs in pregnant women and its association to autism have been explored. Previous studies have shown an increased blood level of serotonin in individuals affected with autism spectrum disorder, warranting the exploration of a possible association .
The risk of autism spectrum disorders was shown to be doubled with maternal use of SSRIs in a recent case controlled study of 298 children, with prenatal exposure reported for 20 of those children . This was seen by evaluating medical records, considering both the SSRI exposure and the mental health history of the mother, and pointing to a high association with SSRI treatment and autism during the first trimester. However, the sample size for this study is small. A recent study conducted in Sweden by Rai et al.  expanded on this and illustrated a case control study of 4429 children with autism. It demonstrated an association between in utero exposure to both SSRIs and nonselective monoamine reuptake inhibitors with an increased risk of autism spectrum disorders, particularly without intellectual disability. However, there is again a limitation with interpreting medical records, such as prescribed versus actual use of SSRIs.
Further, other studies using animal models show that preclinical findings in rodents exposed to SSRIs during development point to an increase in depression and anxiety, exhibiting alteration in social behaviors in the offspring. The data show adverse effects of maternal mental illness on pregnancy outcomes and infant neurodevelopment but are not robust enough to discourage the use of SSRIs during human pregnancy . In a study by Gur et al. , it was shown that the manipulation of serotonin during early development in both in vitro and in vivo models disturbs characteristic chemoarchitectural and electrophysiological brain features. This includes changes in raphe and callosal connections, sensory processing, myelin sheath formation, neophobia, and disrupted juvenile play behavior. These findings indicate that serotonin homeostasis is necessary for proper brain maturation and fetal development. Although SSRIs are not contraindicated for use during pregnancy, the effects should be examined more carefully . In a similar study done by Simpson et al. , animal models were used to study the importance of serotonin homeostasis for the development of rat pups’ brains. It was demonstrated that when the serotonin levels were altered by SSRIs during early development of brain structure, the functions were altered. This alteration was also more evident in males than in females. This suggests that SSRIs may have similar effects in human neonates .
Conversely, other recent studies have suggested that there may actually not be a strong association between SSRI intake and the subsequent development of autism. A recent cohort study of live births in Denmark from 1996 to 2005 involving 3,892 cases of ASD found no significant association, as only 52 cases of SSRI use were found . Larger observational studies are required to establish a true link between the use of SSRIs and autism. Furthermore, it must be noted that the effect of depression itself as a factor in autism separate from the administration of SSRIs is a possibility. Thus, it may be that, in some cases, depression itself or other concomitant factors have a combined effect that is not necessarily due to the use of SSRIs.
2.7. Artificial Insemination and Fertility Medications
There is an increase in prevalence in the number of women utilizing fertility measures, thus calling for studies to determine the association between assisted reproductive therapy and neurodevelopmental complications, and more specifically autism. A nested case control study done by Lyall et al.  shows that assisted reproductive therapy and a history of infertility do not increase the risk for autism spectrum disorders. However, the age of the mother needs to be taken into consideration, as artificial insemination among older mothers has been studied to lead to more complications. Women under the age of 35 using fertility therapies such as ovulation inducing drugs and artificial insemination did not increase the risk for having a child with autism, while researchers suggest that the rise in fertility treatments in older women above 35 may increase the risk of having a child with autism for those using artificial insemination and/or ovulation inducing drugs. While the study is strong in that it uses a large national sample, it is important to note that both diagnoses and fertility treatments were self-reported . Conversely, a recent cohort study conducted by Bay et al. showed a statistically significant increase in autism and other mental health disorders following ovulation induction . This was done through a cohort study using 555,828 children in Denmark using information from a birth register and evaluated with statistical analyses. There were no significant associations found with in vitro fertilization/intracytoplasmic sperm injection (ICSI) or with cryopreserved embryos or gametes, types of hormones, or cause of infertility. The strength in this study includes long followup and low risk of selection bias, but numerous subgroup analyses may lead to risk of chance influencing significant associations.
In an epidemiological study conducted in India by Mamidala et al., maternal hormonal intervention was a significant risk factor for ASD, possibly due to maternal hormone disturbances causing obstetric complications, which in turn are a risk for ASD . While there was a large sample size, there was an absence of detailed information on dosage and frequency of hormonal intervention.
Thus, with differing results it is evident that more specific studies need to be conducted on infertility treatments keeping in mind specific subtypes and their effect on autism in children. Controls for age can also be accounted for, and adverse effects can be more accurately studied in the future.
2.8. Meconium Aspiration Syndrome
Meconium aspiration syndrome, which occurs when a fetus who is under stress and not getting enough oxygen inhales waste products inside the womb, was linked to a sevenfold increase in the likelihood that a child would later develop autism. A study examined the incidence of autism in the neonatal intensive care unit and risk factors connected with autistic development. Findings in this study indicate that children with autism had a significantly higher history of meconium aspiration syndrome than the controls . However, there is insufficient evidence to implicate any one perinatal or neonatal factor in autism etiology, although there is some evidence to suggest that exposure to a broad class of conditions reflecting general compromises to perinatal and neonatal health may increase the risk. Therefore meconium aspiration syndrome cannot be the cause of autistic disorder in children, but it can be a contributing factor .
2.9. Birth Weight
Many studies have evaluated the association between birth weight and the development of autism. A significant fourfold increased risk was observed in low birth weight females for autism accompanied by mental retardation. In low birth weight males there was no significant increased risk observed for autism alone. Though this implies a certain etiological premise of difference in gender, it is also important to note that while the population cohort design is strong, there was not a large number overall of the lower birth weight categories in females . An earlier study by Wilkerson supports this finding as it determined that birth weight was a factor for the risk of autism spectrum disorders, with significant associations between autism and gestational age, maternal morphology and intrauterine stress. Specifically, it is the prescriptions taken during pregnancy, the length of labor, viral infection, abnormal presentation at delivery, and finally low birth weight that were associated with autism. In this study only 183 autistic children were considered and medical conditions of the mother based on a maternal self-report .
Further, several studies examined head circumference and height abnormalities in autism patients. Their studies suggest that the abnormal growth in children with autism spectrum disorders may be related to the causal factors that also increase the risk for ASD, as it was found that children with ASD had proportionally smaller head circumference compared to height during their first year of life, which was absent in premature/low birth weight children with ASD. Even more importantly, the body grew faster than the head for those with ASD by the end of the first year of life, suggesting a closer following of length to circumference during development. However, there may have been some recall bias and head circumference could only be measured on the first year of life all within a modest sample size, indicating a need for replicating the study in a larger cohort .
Similar studies were conducted illustrating that relative microcephaly was more frequent in children with ASD. However microcephaly can also be caused by other factors such as low intelligence and heredity, which could not be controlled for, and also only focused on measurements obtained at birth . Expanding on this, a matched case control studies of children in Stockholm county showed a correlation between low growth for gestation age and preterm birth with ASD combined with intellectual disabilities. The strength of this study lies in its comprehensive sample and size but did not measure some other maternal factors such as substance abuse and nutritional influence .
Several other studies have focused on maternal changes during pregnancy and their association with autism. A population-based study in Utah (US) looked at prenatal variables of autistic children and focused on gestational weight. It was found that maternal prenatal weight gain, but not prepregnancy body mass index, is directly related to an increased risk of ASD. Because of use of cohort and control groups, it not only allowed a representative sample of Utah children, but also as a surveillance study could not directly assess cases and controls . However, a recent longitudinal study using birth data from 4800 children from the United States showed that children born to over-/underweight mothers during prepregnancy had increased incidences of being born with a low birth weight. The group noted that low birth weight increased chances of developing ASD, as well as rapid head growth. This study concluded that abnormal maternal gestational weight indirectly caused an increased chance of developing ASD . In addition to a lower birth weight population, a secondary analysis longitudinal design study using cranial ultrasound evidence of 14 study participants diagnosed with ASD identified that children with ventricular enlargement were strong indicators of the potential risk for autism spectrum disorders .
Overall, these birth weight studies illustrate that more research with larger populations needs to be conducted to determine whether autism etiology is genetic in relation to birth weight, whether birth weight is a risk factor or a cause of autism, how much mother’s gestational age plays a role, and whether pre- or postpregnancy weight of the mother has a larger effect on prevalence of autism and ASD as research currently supports a variety of findings.
2.10. Labor Induction and Augmentation
Since the early 1990s, a number of studies have suggested the link between ASD and labor induction, such as the use of oxytocin . The research that ensued found significantly different results between population-based studies and clinic based studies. Gardener et al.’s analysis showed induction increase in the risk of autism by 72% in three clinic based studies, while the selected population-based studies reported no association . Recently, however, labor induction was positively correlated with autism in a large population study comparing birth records in North Carolina (1990–1998) and corresponding school records of autistic children (1997–2007). The study controlled for environmental factors such as socioeconomic status, maternal health, pregnancy-related events and conditions, and birth year. The authors reported that the link was particularly significant in males. The lack of differentiation of underlying complications in pregnancy, which lead to eventual use of induction, could be the cause of these conflicting findings . Juul-Dam et al. summarized causes of prolonged labor, including “fetal malposition, fetopelvic disproportion, excess sedation, inadequate contraction, and rupture of fetal membranes before the onset of active labor.” However, these complications differ in severity and may require varied quantity of induction agent used at distinctive stages of labor. Further research is necessary to differentiate between the underlying obstetric complications that lead to the eventual use of induction and their respective potential association with autism .
2.11. Labor Time
A review of literature found limited number of researches on the topic of labor time and autism. The few identified studies abound with conflicting evidence. The research done by Glasson et al. purports that labor duration of less than 1 hour carries an increased risk of developing ASD . On the other hand, Wilkerson et al. found that a prolonged labor (greater than 18–24 hours) resulted in an increased risk for autism . One of the latest cohort studies on the topic that involved 268 subjects also suggests positive association between prolonged labor and autism . However, among Gardener et al.’s meta-analysis of nine studies on this subject, five have neutral results, only three have positive association, and one has negative association .
Current understanding suggests that hypoxia is one of the complications of prolonged labor, along with infection, or head trauma from extended pressure. All of these complications could lead to permanent damages in the neonates’ developing brain . Neonatal oxygen deprivation can be quantified by several measurements, including low Apgar score, fetal distress, caesarian delivery, threatened abortion, and hemorrhage during pregnancy . Four large cohort studies conducted across Sweden, Australia, and Denmark found that an Apgar score of 7 has a strong predictive value of autism [18, 54–56]; similar findings were reported by Garderner et al. . Finally, Guinchat et al.  hypothesize that the increased prevalence of autism may be in part due to higher success in obstetric and neonatal care, which resulted in an increased survival rates of hypoxic neonates with brain damage.
In summary, some investigations have shown an association between length of labor and autism, but findings have been inconsistent owing to differences in sampling and methods. While there is still room for much further research, current understanding suggests that length of labor is possibly associated with autism. Prolonged delivery due to oversedation, inappropriate position of the fetus, and unbalanced fetopelvic size and oversedation, which results in induction, can play a role. It is also possible that children who become autistic may also be slow to deliver that the prolonged delivery is a symptom of, rather than a cause of, autism.
In summary, several attributes of the perinatal and labor experiences may be associated with the development of autism. Yet, importantly, these factors may work separately or may work together with other stimuli. Table 1 provides a summary of the findings in the studies explored in this article.
While association between β2 adrenergic receptor agonists and autism spectrum disorders is not strong, exposure to terbutaline during the third trimester has shown to increase incidence. Furthermore terbutaline has been shown to increase microglial activation associated with behavioral abnormalities akin to autism. Labor induction and augmentation appear to be an area of association. While one study showed that children whose mothers received augmented and/or induced childbirth showed a greater risk for autism compared with controls, further research is needed to prove an association. The role of maternal disease cannot be ignored as antiphospholipid syndrome and perinatal inflammation may have important roles in the eventual development of autism. Antiepileptic drugs and oral supplements may play a role in later onset. Cocaine has been associated with an increase in the onset of neurodevelopmental abnormalities, but the direct influence on autism development is still lacking. While a link between smoking and autism could not be established, air pollution may have a role. Several studies have implicated SSRIs in autism, but a larger recent cohort study showed no association. Artificial insemination and fertility medications were largely found to have to link, yet reports are conflicted. Prolonged labor may also lead to neurological deficits and thus autism.
Attributes of the delivery room and birthing experience also may have a role in autism. While some evidence suggests that meconium aspiration syndrome may have a link as a contributing factor, more studies are needed. Birth weight, gestational age, and preterm birth may correlate with autism and intellectual disabilities.
The identification of prenatal factors that are linked to autism may serve as a paradigm shift in our current view and management of autism. The fact that several risk factors during the prenatal and labor periods are implicated in autism should prompt the medical community to focus on the pregnancy and labor periods as preventive measures to curb the incidence of autism.
|ASD:||Autism spectrum disorder|
|SSRI:||Selective serotonin reuptake inhibitor|
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
The authors acknowledge Chris Burnett, BS for assistance with search for references and Disease Discovery through Innovation and Creativity (DDIC) Study Group.
- D. K. Kinney, K. M. Munir, D. J. Crowley, and A. M. Miller, “Prenatal stress and risk for autism,” Neuroscience and Biobehavioral Reviews, vol. 32, no. 8, pp. 1519–1532, 2008.
- V. Guinchat, P. Thorsen, C. Laurent, C. Cans, N. Bodeau, and D. Cohen, “Pre-, peri- and neonatal risk factors for autism,” Acta Obstetricia et Gynecologica Scandinavica, vol. 91, no. 3, pp. 287–300, 2012.
- D. Bilder, J. Pinborough-Zimmerman, J. Miller, and W. McMahon, “Prenatal, perinatal, and neonatal factors associated with autism spectrum disorders,” Pediatrics, vol. 123, no. 5, pp. 1293–1300, 2009.
- A. L. Roberts, K. Lyall, J. W. Rich-Edwards, A. Ascherio, and M. G. Weisskopf, “Association of maternal exposure to childhood abuse with elevated risk for autism in offspring,” JAMA Psychiatry, vol. 70, no. 5, pp. 508–515, 2013.
- F. I. Roullet, J. K. Y. Lai, and J. A. Foster, “In utero exposure to valproic acid and autism—a current review of clinical and animal studies,” Neurotoxicology and Teratology, vol. 36, pp. 47–56, 2013.
- J. Christensen, T. K. Grnøborg, M. J. Srøensen et al., “Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism,” Journal of the American Medical Association, vol. 309, no. 16, pp. 1696–1703, 2013.
- K. Williams, M. Helmer, G. W. Duncan, J. K. Peat, and C. M. Mellis, “Perinatal and maternal risk factors for autism spectrum disorders in New South Wales, Australia,” Child: Care, Health and Development, vol. 34, no. 2, pp. 249–256, 2008.
- E. J. Glasson, C. Bower, B. Petterson, N. de Klerk, G. Chaney, and J. F. Hallmayer, “Perinatal factors and the development of autism: a population study,” Archives of General Psychiatry, vol. 61, no. 6, pp. 618–627, 2004.
- N. G. S. Haglund and K. B. M. Källén, “Risk factors for autism and Asperger syndrome: perinatal factors and migration,” Autism, vol. 15, no. 2, pp. 163–183, 2011.
- K. M. Lampi, A. Sourander, M. Gissler et al., “Brief report: validity of Finnish registry-based diagnoses of autism with the ADI-R,” Acta Paediatrica, vol. 99, no. 9, pp. 1425–1428, 2010.
- N. Gunnes, P. Suren, M. Bresnahan et al., “Interpregnancy interval and risk of autistic disorder,” Epidemiology, vol. 24, no. 6, pp. 906–912, 2013.
- A. T. Langridge, E. J. Glasson, N. Nassar et al., “Maternal conditions and perinatal characteristics associated with autism spectrum disorder and intellectual disability,” PLoS ONE, vol. 8, no. 1, Article ID e50963, 2013.
- M. P. Mamidala, A. Polinedi, P. T. V. Praveen Kumar et al., “Prenatal, perinatal and neonatal risk factors of Autism Spectrum Disorder: a comprehensive epidemiological assessment from India,” Research in Developmental Disabilities, vol. 34, no. 9, pp. 3004–3013, 2013.
- P. Polo-Kantola, E. Rauhala, R. Erkkola, K. Irjala, and O. Polo, “Estrogen replacement therapy and nocturnal periodic limb movements: a randomized controlled trial,” Obstetrics and Gynecology, vol. 97, no. 4, pp. 548–554, 2001.
- T. A. May-Benson, J. A. Koomar, and A. Teasdale, “Incidence of pre-, peri-, and post-natal birth and developmental problems of children with sensory processing disorder and children with autism spectrum disorder,” Frontiers in Integrative Neuroscience, vol. 3, p. 31, 2009.
- M. W. Kuzniewicz, S. Wi, Y. Qian, E. M. Walsh, M.A. Armstrong, and L. A. Croen, “Prevalence and neonatal factors associated with autism spectrum disorders in preterm infants,” The Journal of Pediatrics, vol. 164, no. 1, pp. 20–25, 2014.
- Y. M. Al-Farsi, M. M. Al-Sharbati, M. I. Waly et al., “Effect of suboptimal breast-feeding on occurrence of autism: a case-control study,” Nutrition, vol. 28, no. 7-8, pp. e27–e32, 2012.
- D. S. Wilkerson, A. G. Volpe, R. S. Dean, and J. B. Titus, “Perinatal complications as predictors of infantile autism,” International Journal of Neuroscience, vol. 112, no. 9, pp. 1085–1098, 2002.
- X. Zhang, C. Lv, J. Tian et al., “Prenatal and perinatal risk factors for autism in China,” Journal of Autism and Developmental Disorders, vol. 40, no. 11, pp. 1311–1321, 2010.
- H. E. Volk, T. Kerin, F. Lurmann, I. Hertz-Picciotto, R. McConnell, and D. B. Campbell, “Autism spectrum disorder: interaction of air pollution with the MET receptor tyrosine kinase gene,” Epidemiology, vol. 25, no. 1, pp. 44–47, 2014.
- A. L. Roberts, K. Lyall, J. E. Hart et al., “Perinatal air pollutant exposures and autism spectrum disorder in the children of Nurses' Health Study II participants,” Environmental Health Perspectives, vol. 121, no. 8, pp. 978–984, 2013.
- B. Bergman, H. Bokström, O. Borgå, L. Enk, T. Hedner, and B. Wängberg, “Transfer of terbutaline across the human placenta in late pregnancy,” Obstetrical & Gynecological Survey, vol. 40, no. 2, pp. 69–71, 1985.
- M. C. Zerrate, M. Pletnikov, S. L. Connors et al., “Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism,” Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 1, pp. 16–22, 2007.
- S. L. Connors, D. E. Crowell, C. G. Eberhart et al., “β2-Adrenergic receptor activation and genetic polymorphisms in autism: data from dizygotic twins,” Journal of Child Neurology, vol. 20, no. 11, pp. 876–884, 2005.
- K. Cheslack-Postava, M. D. Fallin, D. Avramopoulos et al., “β2-Adrenergic receptor gene variants and risk for autism in the AGRE cohort,” Molecular Psychiatry, vol. 12, no. 3, pp. 283–291, 2007.
- L. A. Croen, S. L. Connors, M. Matevia, Y. Qian, C. Newschaffer, and A. W. Zimmerman, “Prenatal exposure to β2-adrenergic receptor agonists and risk of autism spectrum disorders,” Journal of Neurodevelopmental Disorders, vol. 3, no. 4, pp. 307–315, 2011.
- F. R. Witter, A. W. Zimmerman, J. P. Reichmann, and S. L. Connors, “In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes,” American Journal of Obstetrics & Gynecology, vol. 201, no. 6, pp. 553–559, 2009.
- N. Abisror, A. Mekinian, E. Lachassinne et al., “Autism spectrum disorders in babies born to mothers with antiphospholipid syndrome,” Seminars in Arthritis and Rheumatism, vol. 43, no. 3, pp. 348–351, 2013.
- A. S. Brown, A. Sourander, S. Hinkka-Yli-Salomäki, I. W. McKeague, J. Sundvall, and H. Surcel, “Elevated maternal C-reactive protein and autism in a national birth cohort,” Molecular Psychiatry, vol. 19, no. 2, pp. 259–264, 2014.
- R. Banach, A. Thompson, P. Szatmari et al., “Brief report: relationship between non-verbal IQ and gender in autism,” Journal of Autism and Developmental Disorders, vol. 39, no. 1, pp. 188–193, 2009.
- A. D. Rasalam, H. Hailey, J. H. G. Williams et al., “Characteristics of fetal anticonvulsant syndrome associated autistic disorder,” Developmental Medicine and Child Neurology, vol. 47, no. 8, pp. 551–555, 2005.
- P. Surén, C. Roth, M. Bresnahan et al., “Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children,” The Journal of the American Medical Association, vol. 309, no. 6, pp. 570–577, 2013.
- E. Davis, I. Fennoy, D. Laraque, N. Kanem, G. Brown, and J. Mitchell, “Autism and developmental abnormalities in children with perinatal cocaine exposure.,” Journal of the National Medical Association, vol. 84, no. 4, pp. 315–319, 1992.
- P. L. Tran, V. Lehti, K. M. Lampi et al., “Smoking during pregnancy and risk of autism spectrum disorder in a finnish national birth cohort,” Paediatric and Perinatal Epidemiology, vol. 27, no. 3, pp. 266–274, 2013.
- H. E. Volk, F. Lurmann, B. Penfold, I. Hertz-Picciotto, and R. McConnell, “Traffic-related air pollution, particulate matter, and autism,” Archives of General Psychiatry, vol. 70, no. 1, pp. 71–77, 2013.
- L. A. Croen, J. K. Grether, C. K. Yoshida, R. Odouli, and V. Hendrick, “Antidepressant use during pregnancy and childhood autism spectrum disorders,” Archives of General Psychiatry, vol. 68, no. 11, pp. 1104–1112, 2011.
- D. Rai, B. K. Lee, C. Dalman, J. Golding, G. Lewis, and C. Magnusson, “Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study,” BMJ, vol. 346, no. 7907, Article ID f2059, 2013.
- K. L. Simpson, K. J. Weaver, E. De Villers-Sidani et al., “Perinatal antidepressant exposure alters cortical network function in rodents,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 45, pp. 18465–18470, 2011.
- A. Hviid, M. Melbye, and B. Pasternak, “Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism,” The New England Journal of Medicine, vol. 369, no. 25, pp. 2406–2415, 2013.
- K. Lyall, D. L. Pauls, D. Spiegelman, S. L. Santangelo, and A. Ascherio, “Fertility therapies, infertilityand autism spectrum disorders in the Nurses' Health Study II,” Paediatric and Perinatal Epidemiology, vol. 26, no. 4, pp. 361–372, 2012.
- B. Bay, E. L. Mortensen, D. Hvidtjørn, and U. S. Kesmodel, “Fertility treatment and risk of childhood and adolescent mental disorders: Register based cohort study,” British Medical Journal, vol. 347, no. 7917, Article ID f3978, 2013.
- M. P. Mamidala, A. Polinedi, P. T. V. Praveen Kumar et al., “Maternal hormonal interventions as a risk factor for Autism Spectrum Disorder: an epidemiological assessment from India,” Journal of Biosciences, vol. 38, no. 5, pp. 887–892, 2013.
- T. Matsuishi, Y. Yamashita, Y. Ohtani et al., “Incidence of and risk factors for autistic disorder in neonatal intensive care unit survivors,” Journal of Autism and Developmental Disorders, vol. 29, no. 2, pp. 161–166, 1999.
- D. Schendel and T. K. Bhasin, “Birth weight and gestational age characteristics of children with autism, including a comparison with other developmental disabilities,” Pediatrics, vol. 121, no. 6, pp. 1155–1164, 2008.
- M. Schrieken, J. Visser, I. Oosterling et al., “Head circumference and height abnormalities in autism revisited: the role of pre- and perinatal risk factors,” European Child and Adolescent Psychiatry, vol. 22, no. 1, pp. 35–43, 2013.
- M. Grandgeorge, E. Lemonnier, and N. Jallot, “Autism spectrum disorders: head circumference and body length at birth are both relative,” Acta Paediatrica, vol. 102, no. 9, pp. 901–907, 2013.
- K. M. Abel, C. Dalman, A. C. Svensson et al., “Deviance in fetal growth and risk of autism spectrum disorder,” The American Journal of Psychiatry, vol. 170, no. 4, pp. 391–398, 2013.
- D. A. Bilder, A. V. Bakian, J. Viskochil et al., “Maternal prenatal weight gain and autism spectrum disorders,” Pediatrics, vol. 132, no. 5, pp. e1276–e1283, 2013.
- B. G. Moss and D. C. Chugani, “Increased risk of very low birth weight, rapid postnatal growth, and autism in underweight and obese mothers,” American Journal of Health Promotion, vol. 28, no. 3, pp. 181–188, 2014.
- T. Z. Movsas, J. A. Pinto-Martin, A. H. Whitaker et al., “Autism spectrum disorder is associated with ventricular enlargement in a low birth weight population,” The Journal of Pediatrics, vol. 163, no. 1, pp. 73–78, 2013.
- S. G. Gregory, R. Anthopolos, C. E. Osgood, C. A. Grotegut, and M. L. Miranda, “Association of autism with induced or augmented childbirth in North Carolina Birth Record (1990–1998) and Education Research (1997–2007) databases,” JAMA Pediatrics, vol. 167, no. 10, pp. 959–966, 2013.
- N. Juul-Dam, J. Townsend, and E. Courchesne, “Prenatal, perinatal, and neonatal factors in autism, pervasive developmental disorder-not otherwise specified, and the general population,” Pediatrics, vol. 107, no. 4, article e63, 2001.
- L. A. Maramara, W. He, and X. Ming, “Pre- and perinatal risk factors for autism spectrum disorder in a New Jersey cohort,” Journal of Child Neurology, 2014.
- W. W. Eaton, P. B. Mortensen, P. H. Thomsen, and M. Frydenberg, “Obstetric complications and risk for severe psychopathology in childhood,” Journal of Autism and Developmental Disorders, vol. 31, no. 3, pp. 279–285, 2001.
- C. M. Hultman, P. Sparén, and S. Cnattingius, “Perinatal risk factors for infantile autism,” Epidemiology, vol. 13, no. 4, pp. 417–423, 2002.
- H. J. Larsson, W. W. Eaton, K. M. Madsen et al., “Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status,” American Journal of Epidemiology, vol. 161, no. 10, pp. 916–925, 2005.
- H. Gardener, D. Spiegelman, and S. L. Buka, “Perinatal and neonatal risk factors for autism: a comprehensive meta-analysis,” Pediatrics, vol. 128, no. 2, pp. 344–355, 2011.
- G. Russell, C. Steer, and J. Golding, “Social and demographic factors that influence the diagnosis of autistic spectrum disorders,” Social Psychiatry and Psychiatric Epidemiology, vol. 46, no. 12, pp. 1283–1293, 2011.
- M. F. Casanova, A. S. El-Baz, S. S. Kamat et al., “Focal cortical dysplasias in autism spectrum disorders,” Acta Neuropathologica Communications, vol. 1, no. 1, p. 67, 2013.
- B. Tang, C. C. Piazza, D. Dolezal, and M. T. Stein, “Severe feeding disorder and malnutrition in 2 children with autism,” Journal of Developmental and Behavioral Pediatrics, vol. 32, no. 3, pp. 264–267, 2011.
- P. Rodier, R. K. Miller, and R. L. Brent, “Does treatment of premature labor with terbutaline increase the risk of autism spectrum disorders?” Obstetric Anesthesia Digest, vol. 31, no. 4, pp. 211–212, 2011.
- L. H. F. Cohen, E. Vamos, C. Heinrichs et al., “Growth failure, encephalopathy, and endocrine dysfunctions in two siblings, one with 5-oxoprolinase deficiency,” European Journal of Pediatrics, vol. 156, no. 12, pp. 935–938, 1997.
- S. J. Meldrum, T. Strunk, A. Currie, S. L. Prescott, K. Simmer, and A. J. Whitehouse, “Autism spectrum disorder in children born preterm-role of exposure to perinatal inflammation,” Frontiers in Neuroscience, vol. 7, article 123, 2013.
- S. Gentile, “Drug treatment for mood disorders in pregnancy,” Current Opinion in Psychiatry, vol. 24, no. 1, pp. 34–40, 2011.
- K. S. L. Lam, M. G. Aman, and L. E. Arnold, “Neurochemical correlates of autistic disorder: a review of the literature,” Research in Developmental Disabilities, vol. 27, no. 3, pp. 254–289, 2006.
- T. L. Gur, D. R. Kim, and C. N. Epperson, “Central nervous system effects of prenatal selective serotonin reuptake inhibitors: sensing the signal through the noise,” Psychopharmacology, vol. 227, no. 4, pp. 567–582, 2013.
- J. A. Bartz and E. Hollander, “Oxytocin and experimental therapeutics in autism spectrum disorders,” in Progress in Brain Research, D. N. Inga and L. Rainer, Eds., vol. 170, pp. 451–462, Elsevier, New York, NY, USA, 2008.
- A. Kolevzon, R. Gross, and A. Reichenberg, “Prenatal and perinatal risk factors for autism: a review and integration of findings,” Archives of Pediatrics and Adolescent Medicine, vol. 161, no. 4, pp. 326–333, 2007.
Copyright © 2014 Naveen Dhawan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.